Spots Global Cancer Trial Database for selumetinib
Every month we try and update this database with for selumetinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery | NCT01206140 | Recurrent Adult... Stage III Adult... Stage IV Adult ... | Laboratory Biom... Selumetinib Temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib | NCT01519427 | Recurrent Melan... Stage IIIA Mela... Stage IIIB Mela... Stage IIIC Mela... Stage IV Melano... | Akt inhibitor M... selumetinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors | NCT01217450 | Recurrent Colon... Recurrent Recta... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta... Unspecified Adu... | selumetinib cetuximab laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC) | NCT03004105 | Malignant Neopl... Advanced Lung C... Recurrent Nonsm... | Selumetinib Durvalumab Phone Calls | 18 Years - | M.D. Anderson Cancer Center | |
| Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study | NCT01949870 | Inoperable Loca... | Cisplatin Gemcitabine Selumetinib | 20 Years - 130 Years | AstraZeneca | |
| Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC | NCT02337530 | Non-Small Cell ... | Selumetinib Pemetrexed Cisplatin Carboplatin | 18 Years - | Canadian Cancer Trials Group | |
| Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer | NCT01843062 | Differentiated ... | Selumetinib Placebo Radioactive Iod... | 18 Years - 130 Years | AstraZeneca | |
| Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas | NCT05253131 | MPNST NF1 Sarcoma | Selumetinib | 18 Years - 99 Years | University of Alabama at Birmingham | |
| Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer | NCT00551070 | Borderline Ovar... Low Grade Ovari... Micropapillary ... Primary Periton... Primary Periton... Recurrent Borde... | Laboratory Biom... Pharmacological... Selumetinib Selumetinib Sul... | 19 Years - | National Cancer Institute (NCI) | |
| A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers | NCT02583542 | Triple-Negative... Squamous Cell L... Non-squamous Ce... Non-squamous Ce... | AZD2014 AZD6244 | 18 Years - | Queen Mary University of London | |
| Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma | NCT01089101 | Low Grade Gliom... Recurrent Child... Recurrent Neuro... Recurrent Visua... Refractory Neur... Refractory Visu... | Biospecimen Col... Selumetinib | 3 Years - 21 Years | National Cancer Institute (NCI) | |
| Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer | NCT00604721 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | selumetinib pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy | NCT01658943 | Pancreatic Acin... Pancreatic Duct... Recurrent Pancr... Stage IV Pancre... | Akt Inhibitor M... Fluorouracil Oxaliplatin Selumetinib | 18 Years - | National Cancer Institute (NCI) | |
| Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer | NCT03801369 | Anatomic Stage ... Metastatic Trip... | Biopsy Capivasertib Ceralasertib Durvalumab Olaparib Quality-of-Life... Selumetinib | 18 Years - | OHSU Knight Cancer Institute | |
| Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer | NCT02393690 | Metastatic Thyr... Poorly Differen... Recurrent Thyro... Stage IV Thyroi... Stage IV Thyroi... Stage IVA Thyro... Stage IVA Thyro... Stage IVB Thyro... Stage IVB Thyro... Stage IVC Thyro... Stage IVC Thyro... | Iodine I-131 Placebo Adminis... Selumetinib | 18 Years - | Academic and Community Cancer Research United | |
| MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma | NCT00866177 | Recurrent Melan... Stage III Skin ... Stage IV Skin M... | Laboratory Biom... Selumetinib | 18 Years - | National Cancer Institute (NCI) | |
| National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer | NCT02664935 | Non-Small Cell ... Carcinoma, Squa... Adenocarcinoma | AZD4547 Vistusertib Palbociclib Crizotinib Selumetinib Docetaxel AZD5363 Osimertinib Durvalumab Sitravatinib AZD6738 | 18 Years - | University of Birmingham | |
| Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC | NCT01783197 | Non Small Cell ... | Paclitaxel Carboplatin Selumetinib Pemetrexed Cisplatin | 18 Years - | Canadian Cancer Trials Group | |
| National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer | NCT02664935 | Non-Small Cell ... Carcinoma, Squa... Adenocarcinoma | AZD4547 Vistusertib Palbociclib Crizotinib Selumetinib Docetaxel AZD5363 Osimertinib Durvalumab Sitravatinib AZD6738 | 18 Years - | University of Birmingham | |
| Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV | NCT01166126 | Mucosal Melanom... Recurrent Melan... Stage IV Melano... | temsirolimus selumetinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors | NCT03433183 | Malignant Perip... Neurofibromatos... | Selumetinib Sirolimus | 12 Years - | Sarcoma Alliance for Research through Collaboration | |
| A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer | NCT02151084 | Biliary Tract C... Gallbladder Car... | Selumetinib Cisplatin Gemcitabine | 18 Years - | University Health Network, Toronto | |
| SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer | NCT02299999 | Metastatic Brea... | AZD2014 AZD4547 AZD5363 AZD8931 Selumetinib Vandetanib Bicalutamide Olaparib Anthracyclines Taxanes cyclophosphamid... DNA intercalato... Methotrexate vinca alkaloids Platinum based ... Bevacizumab Mitomycin C Eribulin MEDI4736 | 18 Years - | UNICANCER | |
| A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers | NCT02583542 | Triple-Negative... Squamous Cell L... Non-squamous Ce... Non-squamous Ce... | AZD2014 AZD6244 | 18 Years - | Queen Mary University of London | |
| To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects | NCT02063204 | Solid Tumours | selumetinib | 18 Years - | AstraZeneca | |
| Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study | NCT01949870 | Inoperable Loca... | Cisplatin Gemcitabine Selumetinib | 20 Years - 130 Years | AstraZeneca | |
| SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients | NCT02117167 | Non-small Cell ... | AZD2014 AZD4547 AZD5363 AZD8931 Selumetinib Vandetanib Standard mainte... Pemetrexed Durvalumab savolitinib Olaparib | 18 Years - | UNICANCER | |
| A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer | NCT03392246 | Non-small Cell ... | Osimertinib Selumetinib | 18 Years - | Dana-Farber Cancer Institute | |
| AZD9291 in Combination With Ascending Doses of Novel Therapeutics | NCT02143466 | Advanced Non Sm... | Part A - AZD929... Part A - AZD929... Part A - AZD929... Part A - AZD929... Part A - AZD929... Part B - AZD929... Part B - AZD929... Part B - AZD929... Part C - AZD609... Part C - AZD929... Part D - AZD929... | 18 Years - 130 Years | AstraZeneca | |
| Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | NCT01222689 | Adenocarcinoma ... Recurrent Pancr... Stage III Pancr... Stage IV Pancre... | erlotinib hydro... selumetinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC | NCT01933932 | Locally Advance... | Selumetinib Docetaxel Placebo Pegylated G-CSF | 18 Years - 130 Years | AstraZeneca | |
| Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer | NCT02450656 | Colorectal Neop... Gastrointestina... Pancreatic Neop... Carcinoma, Non-... | Afatinib Selumetinib Docetaxel | 18 Years - | The Netherlands Cancer Institute | |
| Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer | NCT02393690 | Metastatic Thyr... Poorly Differen... Recurrent Thyro... Stage IV Thyroi... Stage IV Thyroi... Stage IVA Thyro... Stage IVA Thyro... Stage IVB Thyro... Stage IVB Thyro... Stage IVC Thyro... Stage IVC Thyro... | Iodine I-131 Placebo Adminis... Selumetinib | 18 Years - | Academic and Community Cancer Research United | |
| Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas | NCT04924608 | Neurofibromatos... Plexiform Neuro... | Selumetinib Placebo | 18 Years - | AstraZeneca | |
| Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 | NCT06188741 | Neurofibromatos... Plexiform Neuro... | Selumetinib | 1 Year - 8 Years | University of Alabama at Birmingham | |
| Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery | NCT01859182 | Adenocarcinoma ... Adenocarcinoma ... Adult Primary C... Advanced Adult ... Cholangiocarcin... Localized Unres... Metastatic Extr... Recurrent Adult... Recurrent Extra... Stage II Gallbl... Stage IIIA Gall... Stage IIIB Gall... Stage IVA Gallb... Stage IVB Gallb... Unresectable Ex... | selumetinib Akt inhibitor M... laboratory biom... pharmacogenomic... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) | NCT04590235 | Neurofibromatos... Neurofibroma Pl... | Selumetinib | 3 Years - 99 Years | AstraZeneca | |
| Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors | NCT01217450 | Recurrent Colon... Recurrent Recta... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta... Unspecified Adu... | selumetinib cetuximab laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Selumetinib Paediatric NF1 Japan Study | NCT04495127 | Neurofibromatos... | Selumetinib | 3 Years - 18 Years | AstraZeneca | |
| Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer | NCT03801369 | Anatomic Stage ... Metastatic Trip... | Biopsy Capivasertib Ceralasertib Durvalumab Olaparib Quality-of-Life... Selumetinib | 18 Years - | OHSU Knight Cancer Institute | |
| Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies | NCT01061749 | Adult Solid Neo... | Cixutumumab Laboratory Biom... Pharmacological... Selumetinib | 18 Years - | National Cancer Institute (NCI) | |
| Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | NCT03213691 | Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Recurrent Child... Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim... | Laboratory Biom... Selumetinib Selumetinib Sul... | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas | NCT02407405 | Neurofibromatos... Plexiform Neuro... | Selumetinib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers | NCT02056392 | Solid Tumours | Selumetinib Moxifloxacin selumetinib pla... | 18 Years - 45 Years | AstraZeneca | |
| Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma | NCT01089101 | Low Grade Gliom... Recurrent Child... Recurrent Neuro... Recurrent Visua... Refractory Neur... Refractory Visu... | Biospecimen Col... Selumetinib | 3 Years - 21 Years | National Cancer Institute (NCI) | |
| Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery | NCT01206140 | Recurrent Adult... Stage III Adult... Stage IV Adult ... | Laboratory Biom... Selumetinib Temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Study | NCT05825365 | Neurofibromatos... Plexiform Neuro... Post-operative | Selumetinib Placebo | 3 Years - 18 Years | AstraZeneca | |
| SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients | NCT02117167 | Non-small Cell ... | AZD2014 AZD4547 AZD5363 AZD8931 Selumetinib Vandetanib Standard mainte... Pemetrexed Durvalumab savolitinib Olaparib | 18 Years - | UNICANCER | |
| Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | NCT01278615 | Recurrent Adult... | Laboratory Biom... Selumetinib | 18 Years - | National Cancer Institute (NCI) | |
| Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors | NCT03095248 | Neurofibromatos... Vestibular Schw... Meningioma Ependymoma Glioma | Selumetinib | 3 Years - 45 Years | Children's Hospital Medical Center, Cincinnati | |
| To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers | NCT02093728 | Solid Tumours | selumetinib itraconazole itraconazole selumetinib selumetinib fluconazole fluconazole selumetinib | 18 Years - 45 Years | AstraZeneca | |
| Selumetinib and Olaparib in Solid Tumors | NCT03162627 | Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... | Selumetinib Olaparib | 18 Years - | M.D. Anderson Cancer Center | |
| MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas | NCT02407405 | Neurofibromatos... Plexiform Neuro... | Selumetinib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers | NCT02056392 | Solid Tumours | Selumetinib Moxifloxacin selumetinib pla... | 18 Years - 45 Years | AstraZeneca | |
| Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas | NCT05101148 | Neurofibromatos... | Selumetinib | 12 Years - 17 Years | AstraZeneca | |
| LUMINIST: LUng Cancer Molecular Insights Non Interventional Study | NCT02300831 | NSCLC | Data Collection | - | AstraZeneca | |
| To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects | NCT02063204 | Solid Tumours | selumetinib | 18 Years - | AstraZeneca | |
| Personalized Treatment Selection for Metastatic Breast Cancer | NCT00780676 | Breast Cancer | Dasatinib AZD6244 | 18 Years - | M.D. Anderson Cancer Center | |
| To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers | NCT02046850 | Solid Tumours | selumetinib rifampicin selumetinib rifampicin | 18 Years - 45 Years | AstraZeneca | |
| A Study of Selumetinib in Patients With Kaposi's Sarcoma | NCT01752569 | AIDS-related Ka... | Selumetinib | 18 Years - | Sheffield Teaching Hospitals NHS Foundation Trust | |
| To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers | NCT02046850 | Solid Tumours | selumetinib rifampicin selumetinib rifampicin | 18 Years - 45 Years | AstraZeneca | |
| Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine | NCT00559949 | Recurrent Thyro... Stage I Thyroid... Stage II Thyroi... Stage III Thyro... Stage IV Thyroi... | Laboratory Biom... Selumetinib | 18 Years - | National Cancer Institute (NCI) | |
| Intermittent Selumetinib for Uveal Melanoma | NCT02768766 | Uveal Melanoma | Selumetinib, 10... Selumetinib, 12... Selumetinib, 15... Selumetinib, 17... Selumetinib, 20... Selumetinib, 22... | 18 Years - | Columbia University | |
| Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | NCT01222689 | Adenocarcinoma ... Recurrent Pancr... Stage III Pancr... Stage IV Pancre... | erlotinib hydro... selumetinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours | NCT03326388 | Neurofibromatos... Plexiform Neuro... Optic Nerve Gli... | Selumetinib | 3 Years - 18 Years | Great Ormond Street Hospital for Children NHS Foundation Trust | |
| Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer | NCT02546661 | Muscle Invasive... | AZD4547 MEDI4736 Olaparib AZD1775 Vistusertib AZD9150 Selumetinib | 18 Years - 130 Years | AstraZeneca | |
| Dose-escalation Study to Assess Selumetinib Safety, Tolerability and PK | NCT01960374 | Healthy Volunte... | Selumetinib | 18 Years - 55 Years | AstraZeneca | |
| Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy | NCT01658943 | Pancreatic Acin... Pancreatic Duct... Recurrent Pancr... Stage IV Pancre... | Akt Inhibitor M... Fluorouracil Oxaliplatin Selumetinib | 18 Years - | National Cancer Institute (NCI) | |
| ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer | NCT01242605 | Biliary Tract N... Cholangiocarcin... Gallbladder Neo... | selumetinib gemcitabine cisplatin | 18 Years - | University College, London | |
| Non-interventional Study of Patients With PN NF1 Starting Selumetinib in Russia | NCT05891847 | Neurofibroma | - | AstraZeneca | ||
| Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) | NCT03944772 | Non-Small Cell ... | Osimertinib Savolitinib Gefitinib Necitumumab Durvalumab Carboplatin Pemetrexed Alectinib Selpercatinib Selumetinib Etoposide Cisplatin Datopotamab der... | 18 Years - 130 Years | AstraZeneca | |
| Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies | NCT01364051 | Metastatic Mela... Refractory Mali... Stage IV Cutane... Unresectable Ma... | Cediranib Cediranib Malea... Laboratory Biom... Pharmacological... Selumetinib Selumetinib Sul... | 18 Years - | National Cancer Institute (NCI) | |
| Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine | NCT00559949 | Recurrent Thyro... Stage I Thyroid... Stage II Thyroi... Stage III Thyro... Stage IV Thyroi... | Laboratory Biom... Selumetinib | 18 Years - | National Cancer Institute (NCI) | |
| International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia | NCT03705507 | Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... | Selumetinib Dexamethasone | - | University of Birmingham | |
| Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer | NCT02546661 | Muscle Invasive... | AZD4547 MEDI4736 Olaparib AZD1775 Vistusertib AZD9150 Selumetinib | 18 Years - 130 Years | AstraZeneca | |
| Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma | NCT01089101 | Low Grade Gliom... Recurrent Child... Recurrent Neuro... Recurrent Visua... Refractory Neur... Refractory Visu... | Biospecimen Col... Selumetinib | 3 Years - 21 Years | National Cancer Institute (NCI) | |
| SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors | NCT03433183 | Malignant Perip... Neurofibromatos... | Selumetinib Sirolimus | 12 Years - | Sarcoma Alliance for Research through Collaboration | |
| Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies | NCT01061749 | Adult Solid Neo... | Cixutumumab Laboratory Biom... Pharmacological... Selumetinib | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
